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Abstract: The association between antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
and cancer remains poorly understood. In this study, we searched the Korea National Health
Insurance Claims Database to obtain data for 2097 AAV patients, and evaluated the risk of cancers in
AAV. The standardized incidence ratios (SIRs) of overall and site-specific cancers were estimated in
patients with AAV compared to the general population. The overall risk of cancer was significantly
higher in patients with AAV (SIR 1.90); this remained true in both males (SIR 1.74) and females
(SIR 2.06). For site-specific cancers, the risks of lung (SIR 2.23) and hematological (SIR 11.39) cancers
were higher in AAV patients. For males, the risks of gallbladder and hematological cancers were
increased, while the risks of bladder and hematological cancers were increased in females. Among
AAV subtypes, patients with granulomatosis with polyangiitis had the highest risk of cancers, and
cyclophosphamide, azathioprine/mizoribine, and methotrexate ever-users had increased risk of
overall cancer. The risks of overall and hematological cancers were elevated in AAV patients younger
than 60 years old. Patients with AAV have increased risks of overall, lung, and hematological
cancers. Distinct patterns of cancer incidence are present according to age, sex, AAV subtypes, and
immunosuppressant usage.
Keywords: antineutrophil cytoplasmic antibody; vasculitis; cancer; incidence; risk
1. Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune
disease (AID) with the hallmarks of chronic inflammation within the blood vessels and the production
of ANCAs directed against myeloperoxidase (MPO) and proteinase 3 (PR3) [1]. AAV is classified into
three different disease entities based on the characteristic histologic, serologic, and clinical features [2].
Epidemiologic studies have indicated that AAV mainly affects patients over 50 years old, with an
estimated incidence of 10–20/million and a prevalence of over 100/million [3–5]. Various comorbidities,
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such as cancers, infections, cardiovascular disease, and osteoporosis, are prevalent in patients with
AIDs [6–8]. Among the comorbid conditions, the relationship between AIDs and cancers has attracted
special attention because subjects with AIDs are at higher risk of developing cancers, and the prognosis
of such patients is particularly unfavorable [9]. In addition, there is evidence that cancer can essentially
trigger the development of autoimmunity by affecting the immune system, suggesting a ‘bi-directional’
relationship [10,11]. Meanwhile, the long-term administration of immunosuppressive agents that are
used for the treatment of AIDs is also believed to support the development of cancers [12,13]. For this
reason, continuous efforts have been made to explore the link between AIDs and cancers.
Generally, a significantly higher incidence of cancers has been demonstrated in patients with
AAV [14]. A meta-analysis that analyzed the risk of cancers in patients with AAV showed a higher
overall risk of cancer, specifically non-melanoma skin cancer (NMSC), leukemia, and bladder cancer [15].
Moreover, cyclophosphamide, which is the most widely used therapeutic agent to induce remission
in AAV, is thought to influence the development of cancers [16]. However, there are inconsistencies
in the risks of site-specific malignancies in AAV. Data from the European Vasculitis Study group
have shown that only NMSC was more common in patients with microscopic polyangiitis (MPA)
and granulomatosis with polyangiitis (GPA), while the results from the study by Westman et al. [17]
revealed a higher risk of bladder, testicular, and skin cancer in MPA and GPA [17,18]. Furthermore, a
study by Tatsis et al. suggested that the risk of renal cell carcinoma was elevated in patients with GPA
compared to those with rheumatoid arthritis [19]. Notably, clear geographic and ethnic disparities
have been reported with regard to the demographic factors affecting the link between AAV and cancer.
For instance, although GPA and PR3-ANCA vasculitis are more common in Western countries, MPA
and MPO-ANCA vasculitis are more frequent in Asian countries. In addition, males seem to be more
frequently affected in Western countries, but female patients with AAV are more common in the
Eastern world [20,21]. Moreover, there is considerable variation in the incidence of cancer according
to sex, geographic location, and ethnicity [22,23]. Until recently, because of the rarity of the disease
and the difficulty in diagnosing AAV, the incidence of cancers in patients with AAV has not been well
understood. Therefore, the objective of this study was to evaluate the risk of cancers in Korean patients
with AAV by utilizing the Korea National Health Insurance Claims data.
2. Materials and Methods
2.1. Definition of Patient and the Source of Data
All data were acquired from the database operated by the Health Insurance and Review Agency
(HIRA) in Korea. The HIRA database is a comprehensive database that collects all health care utilization
information registered by Korea’s National Health Insurance (NHI), a mandatory, nationwide health
insurance system. As such, the HIRA database covers nearly the entire population of Korea, containing
information on over 50 million subjects in the country. All medical records are integrated into the HIRA
claims database through the electronic submission of health care utilization information by medical
institutions via electronic form to the NHI for reimbursement purposes. Briefly, the database includes
a wealth of information on all patients, including the following: Hospitalization, ambulatory care,
demographic characteristics, principle diagnoses and comorbidities (International Classification of
Diseases (ICD)-10 codes), drug prescriptions and procedures. Therefore, by using the HIRA database,
it is possible to provide estimates representing the whole spectrum of disease extent and severity in
unselected patient populations [24].
To limit our population to AAV patients, we enrolled patients who were diagnosed with
AAV in a general or tertiary hospital and were prescribed glucocorticoids (methylprednisolone,
hydrocortisone, prednisone, prednisolone, triamcinolone, budesonide, betamethasone, dexamethasone,
and deflazacort). In the identification of MPA, GPA (which is identical to Wegener’s granulomatosis),
and eosinophilic granulomatosis with polyangiitis (EGPA) (which is identical to Churg-Strauss
syndrome), the ICD-10 codes M31.7, M31.3, and M30.1 were used. Regarding immunosuppressive
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agents that were administered to AAV patients after the diagnosis but prior to the development of
cancer, the medications of cyclophosphamide, rituximab, azathioprine/mizoribine, and methotrexate
were defined as AAV medications. Because methotrexate can also be used in the treatment of cancers,
any dose over the standard dose prescribed for the treatment of AAV (>25 mg) was excluded.
The initial date of the registration of the corresponding diagnosis in the HIRA database (index date)
was considered the date of AAV diagnosis. The original source of the population for this study consisted
of all National Health Insurance Claims data from 2008 to 2018. Furthermore, a washout period of 2
years was applied to exclude the previous prevalent cases. As a result, all the data analyzed were from
patients who were diagnosed with AAV between January 2010 and December 2018. This study was
approved by the ethics review board of the Hospital, and the need to obtain informed consent was
waived, owing to the retrospective study design (IRB approval number: 4-2019-0177).
2.2. Cancer Case Ascertainment and Charlson Comorbidity Index
The incidence of cancer in patients with AAV after the diagnosis was investigated from the
National Health Insurance Claims Database and from the 2014 National Cancer Registry (NCR) for the
general population [25]. The definition of cancer occurrence was set as both hospital admission and
the registration of a cancer code (ICD-10: C00–C96) in the National Health Insurance database [26].
In short, all incident cancer cases were defined as those admitted to the hospital for cancer. The medical
conditions included in the Charlson Comorbidity Index (CCI), which is an index that categorizes the
comorbidities of patients based on the ICD codes found in administrative data, were investigated
by searching the corresponding ICD-10 codes of the patients within one year of the AAV index date,
as previously described [27].
2.3. Statistical Analysis
To compare the incidence of cancer in patients with AAV and the general population, we calculated
the standardized incidence ratios (SIRs) of overall and site-specific cancers after dividing patients by age
into 10-year intervals. The observed and expected number of cases were calculated for each age group
using age and sex-specific incidence data. Site-specific cancers were selected based on the 10 most
common cancers in the general population in both males and females, which were included in the 2014
NCR report [25]. Furthermore, in all subgroup analyses, the overall SIR for all types of hematological
cancer (which included Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82–C85, C96), multiple
myeloma (C90), and leukemia (C91–C95)), bladder cancer (C67), and other cancers (remaining cancer
codes) were also calculated. The SIR was estimated by dividing the number of observed cancers by
the number of expected cancers, and the 95% confidence interval (CI) was estimated by the Poisson
distribution. We calculated the number of expected cancer cases by multiplying the age-specific cancer
incidence rate of the general population from the 2014 NCR and the person-years of patients with AAV.
We investigated factors associated with cancer development among patients with AAV using a
nested case-control analysis to avoid length bias. In the nested case-control analysis, age, sex, the index
date of AAV diagnosis, duration, and type of diagnosis were matched. Conditional logistic regression
was performed to estimate the odds ratio (OR) and corresponding 95% CI. A p-value less than 0.05
was considered statistically significant, and SAS Enterprise Guide version 9.4 (SAS Institute Inc., Cary,
NC, USA) and R 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) were used for all
statistical analyses.
3. Results
3.1. Baseline Characteristics of Patients with AAV
In total, 2425 incident cases of AAV were identified during the period from 2010 to 2018. Among
the patients recruited, 328 patients were excluded due to a previous history of cancer before the
diagnosis of AAV. With regard to the type of cancer prior to the diagnosis of AAV, lung cancer
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(C33–C34) was the most common, followed by colon and rectum cancer (C18–C20), prostate cancer
(C61), and non-Hodgkin lymphoma (C82–C85, C96) (Supplementary Figure S1). Among the selected
2097 patients, the mean age was 59.8 years, and the proportion of female patients was 55.7%. In terms
of the subgroups of AAV, 947 (45.2%) patients were diagnosed with MPA, 568 (27.1%) patients were
diagnosed with GPA, and 582 (27.7%) patients were diagnosed with EGPA (Table 1). The mean age at
diagnosis was 64.3, 58.3, and 53.8 years for patients with MPA, GPA, and EGPA, respectively.











Age at diagnosis 59.8 ± 15.6 61.7 ± 13.9 59.7 ± 15.7 0.1723
Sex, n (%)
Female 1168 (55.7) 53 (46.5) 1115 (56.2) 0.0526
Male 929 (44.3) 61 (53.5) 868 (43.8)
Diagnosis, n (%)
MPA 947 (45.2) 38 (33.3) 909 (45.8) 0.0004
GPA 568 (27.1) 49 (43.0) 519 (26.2)
EGPA 582 (27.7) 27 (23.7) 555 (28.0)
Type of insurance, n (%)
National Health Insurance 2004 (95.6) 109 (95.6) 1895 (95.6) 1.0000
Medical Aid 93 (4.4) 5 (4.4) 88 (4.4)
CCI subcategories, n (%) a
Cardiovascular disorder
Myocardial infarction 53 (2.5) 2 (1.8) 51 (2.6) 1.0000
Congestive heart failure 208 (9.9) 16 (14.0) 192 (9.7) 0.1767
Peripheral vascular disease 389 (18.6) 19 (16.7) 370 (18.7) 0.6831
Cerebrovascular disease 303 (14.5) 11 (9.7) 292 (14.7) 0.1732
Diabetes 702 (33.5) 36 (31.6) 666 (33.6) 0.7343
Diabetes with chronic complication 240 (11.4) 11 (9.7) 229 (11.6) 0.6397
Gastrointestinal disorder
Mild liver disease 769 (36.7) 36 (31.6) 733 (37.0) 0.2890
Moderate or severe liver disease 12 (0.6) 1 (0.9) 11 (0.6) 0.4896
Peptic ulcer disease 840 (40.1) 41 (36.0) 799 (40.3) 0.4130
Pulmonary disorder
Chronic pulmonary disease 1420 (67.7) 64 (56.1) 1356 (68.4) 0.0089
Rheumatologic disorder
Rheumatologic disease 330 (15.7) 15 (13.2) 315 (15.9) 0.5187
Kidney disorder
Renal disease except unspecified kidney failure 373 (17.8) 14 (12.3) 359 (18.1) 0.1456
Others
Dementia 86 (4.1) 2 (1.8) 84 (4.2) 0.3247
Hemiplegia or paraplegia 48 (2.3) 1 (0.9) 47 (2.4) 0.5159
Malignancy (nonmetastatic cancer) 0 (0.0) 0 (0.0) 0 (0.0) n/a
Metastatic solid tumor 0 (0.0) 0 (0.0) 0 (0.0) n/a
Acquired immune deficiency syndrome 0 (0.0) 0 (0.0) 0 (0.0) n/a
Medication usage, n (%)
Glucocorticoid steroid usage ≥ 1 year 1037 (49.5) 67 (58.8) 970 (48.9) 0.0511
Cyclophosphamide 1022 (48.7) 63 (55.3) 959 (48.4) 0.1811
Rituximab 250 (11.9) 8 (7.0) 242 (12.2) 0.1303
Azathioprine/mizoribine 835 (39.8) 48 (42.1) 787 (39.7) 0.6785
Methotrexate 293 (14.0) 25 (21.9) 268 (13.5) 0.0173
a The medical conditions included in the CCI score were investigated within one year of the AAV index date.
Values are expressed as the mean ± standard deviation or as the number (percentage). AAV: ANCA-associated
vasculitis; ANCA: Antineutrophil cytoplasmic antibody; MPA: Microscopic polyangiitis; GPA: Granulomatosis
with polyangiitis; EGPA: Eosinophilic granulomatosis with polyangiitis; CCI: Charlson Comorbidity Index; n/a:
Not applicable.
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3.2. Comparison of Variables between AAV Patients with and without Cancer
A total of 114 patients (5.4%) developed cancer after the diagnosis of AAV, and 1983 (94.6%) patients
did not develop cancer during the mean follow-up duration of 3.0 years and 6357.7 person-years
(Supplementary Figure S1). The mean follow-up duration for AAV patients was 1.5 years for those
with cancer and 3.1 years for those without cancer.
The baseline characteristics of AAV patients with cancer and without cancer are described in
Table 1. There were no statistically significant differences regarding the age at diagnosis, sex, type of
insurance, and the medical conditions constituting the CCI, but the proportion of GPA patients was
higher in AAV patients with cancer (43.0% vs. 26.2%). Regarding medication usage, AAV patients
with cancer were more often treated with methotrexate (21.9% vs. 13.5%, p = 0.0173)
3.3. Estimation of Cancer Risk in AAV Patients According to Sex
When we calculated the SIRs of cancers in AAV patients, it was found that the overall cancer risk
was significantly higher than that in the general population (SIR 1.90, 95% CI 1.57–2.28). For site-specific
cancers, the risks of lung cancer (C33–C34) (SIR 2.23, 95% CI 1.34–3.48), hematological cancer (SIR 11.39,
95% CI 7.44–16.69), and the remaining cancers (SIR 3.11, 95% CI 1.97–4.66) were increased. Within
hematological cancer, the risks of non-Hodgkin lymphoma (C82–C85, C96) (SIR 10.14, 95% CI 5.40–17.34)
and multiple myeloma (C90) (SIR 21.12, 95% CI 10.13–38.85) were elevated (Table 2). NMSC (C44) was
only found in one female patient, and the risk for NMSC was not significant.
Table 2. Estimation of cancer risk in AAV patients.
Cancer (ICD-10)
Total
Expected Observed SIR 95% CI
Overall cancer (C00–C96) 60.06 114 1.90 (1.57–2.28)
Stomach (C16) 9.12 9 0.99 (0.45–1.87)
Colon and rectum (C18–C20) 8.41 9 1.07 (0.49–2.03)
Liver (C22) 4.83 4 0.83 (0.23–2.12)
Gallbladder, etc. (C23–C24) 1.97 5 2.54 (0.82–5.93)
Pancreas (C25) 2.03 3 1.48 (0.30–4.32)
Lung (C33–C34) 8.51 19 2.23 (1.34–3.48)
Breast (C50) 3.28 3 0.91 (0.19–2.67)
Ovary (C56) 0.50 2 3.98 (0.48–14.39)
Prostate (C61) 3.84 1 0.26 (0.01–1.45)
Kidney (C64) 1.18 4 3.40 (0.93–8.70)
Bladder (C67) 1.36 4 2.94 (0.80–7.54)
Thyroid (C73) 4.65 2 0.43 (0.05–1.55)
Hematological cancer 2.28 26 11.39 (7.44–16.69)
Hodgkin lymphoma (C81) 0.05 1 21.85 (0.55–121.75)
Non-Hodgkin lymphoma (C82–C85, C96) 1.28 13 10.14 (5.40–17.34)
Multiple myeloma (C90) 0.47 10 21.12 (10.13–38.85)
Leukemia (C91–C95) 0.48 2 4.16 (0.50–15.01)
Other (remaining cancer codes) 7.40 23 3.11 (1.97–4.66)
AAV: ANCA-associated vasculitis; ANCA: Antineutrophil cytoplasmic antibody; ICD: International classification
of diseases.
In male patients with AAV, the risk of overall cancer (SIR 1.74, 95% CI 1.33-2.24) was elevated, and
for site-specific cancers, the risks of gallbladder (C23–C24) (SIR 3.82, 95% CI 1.04-9.78), lung (C33–C34)
(SIR 2.23, 95% CI 1.22–3.74), and hematological cancers (SIR 9.59, 95% CI 4.96–16.76) were higher
compared to those in the general population. On the other hand, although the risk of overall cancer
was also elevated in female patients with AAV, an increased risk of bladder cancer (C67) (SIR 12.05,
95% CI 2.48–35.21) and an increased risk of the remaining cancers (SIR 4.34, 95% CI 2.37–7.28), but not
gallbladder or lung cancers, were observed (Table 3).
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Table 3. Estimation of cancer risk according to sex in AAV.
Cancer (ICD-10)
Male Female
Expected Observed SIR 95% CI Expected Observed SIR 95% CI
Overall cancer (C00–C96) 34.96 61 1.74 (1.33–2.24) 25.79 53 2.06 (1.54–2.69)
Stomach (C16) 6.10 5 0.82 (0.27–1.91) 2.93 4 1.36 (0.37–3.49)
Colon and rectum (C18–C20) 5.00 7 1.40 (0.56–2.88) 3.38 2 0.59 (0.07–2.14)
Liver (C22) 3.35 3 0.89 (0.18–2.62) 1.38 1 0.73 (0.02–4.04)
Gallbladder, etc. (C23–C24) 1.05 4 3.82 (1.04–9.78) 0.92 1 1.08 (0.03–6.04)
Pancreas (C25) 1.08 1 0.93 (0.02–5.17) 0.95 2 2.12 (0.26–7.64)
Lung (C33–C34) 6.29 14 2.23 (1.22–3.74) 2.38 5 2.10 (0.68–4.90)
Breast (C50) 3.57 3 0.84 (0.17–2.46)
Ovary (C56) 0.53 2 3.75 (0.45–13.54)
Prostate (C61) 3.88 1 0.26 (0.01–1.44)
Kidney (C64) 0.77 3 3.90 (0.80–11.40) 0.39 1 2.57 (0.06–14.31)
Bladder (C670 1.14 1 0.88 (0.02–4.90) 0.25 3 12.05 (2.48–35.21)
Thyroid (C73) 0.84 1 1.19 (0.03–6.63) 4.13 1 0.24 (0.01–1.35)
Hematological cancer 1.25 12 9.59 (4.96–16.76) 1.03 14 13.58 (7.42–22.78)
Hodgkin lymphoma (C81) 0.02 1 48.19 (1.22–268.50)
Non-Hodgkin lymphoma (C82–C85, C96) 0.70 6 8.60 (3.16–18.72) 0.59 7 11.95 (4.81–24.63)
Multiple myeloma (C90) 0.25 5 20.01 (6.50–46.70) 0.22 5 22.30 (7.24–52.04)
Leukemia (C91–C95) 0.28 1 3.58 (0.09–19.93) 0.20 1 4.99 (0.13–27.81)
Other (remaining cancer codes) 4.19 9 2.15 (0.98–4.08) 3.23 14 4.34 (2.37–7.28)
AAV: ANCA-associated vasculitis; ANCA: Antineutrophil cytoplasmic antibody; ICD: International classification
of diseases.
3.4. Risk of Cancer Based on AAV Subtypes
Next, we evaluated whether there were differences in the risk of cancer according to AAV subtypes.
In a subgroup analysis, an increased risk of cancer in comparison to that of the general population
was found across the three subtypes of AAV, but the SIR was the highest in patients with GPA
(SIR 2.85, 95% CI 2.11–3.77). Concerning site-specific cancers, only hematological cancer (SIR 5.86,
95% CI 2.15–12.75) was found to be elevated in patients with MPA, whereas the risks of lung (C33–C34)
(SIR 4.17, 95% CI 2.00–7.66), hematological (SIR 18.40, 95% CI 9.51–32.15), and the remaining cancers
(SIR 6.15, 95% CI 3.27–10.51) were higher in GPA patients. Meanwhile, in EGPA patients, the risks of
hematological (SIR 13.20, 95% CI 5.70–26.01) and the remaining cancers (SIR 3.13, 95% CI 1.15–6.82)
were found to be elevated (Table 4).
J. Clin. Med. 2019, 8, 1871 7 of 15
Table 4. Cancer-specific risk based on subgroups of AAV.
Cancer (ICD-10)
MPA GPA EGPA
Expected Observed SIR 95% CI Expected Observed SIR 95% CI Expected Observed SIR 95% CI
Overall cancer (C00–C96) 26.89 38 1.41 (1.00–1.94) 17.19 49 2.85 (2.11–3.77) 15.98 27 1.69 (1.11–2.46)
Stomach (C16) 4.16 5 1.20 (0.39–2.81) 2.61 2 0.77 (0.09–2.77) 2.36 2 0.85 (0.10–3.07)
Colon and rectum (C18–C20) 3.87 4 1.03 (0.28–2.65) 2.40 5 2.08 (0.68–4.86) –
Liver (C22) 2.18 3 1.38 (0.28–4.03) 1.39 1 0.72 (0.02–4.02) –
Gallbladder, etc. (C23–C24) 0.95 2 2.10 (0.25–7.60) 0.55 1 1.80 (0.05–10.05) 0.46 2 4.32 (0.52–15.60)
Pancreas (C25) 0.97 2 2.07 (0.25–7.48) 0.57 1 1.74 (0.04–9.70) –
Lung (C33–C34) 4.09 7 1.71 (0.69–3.53) 2.40 10 4.17 (2.00–7.66) 2.03 2 0.99 (0.12–3.56)
Breast (C50) – 0.97 1 1.03 (0.03–5.74) 1.13 2 1.78 (0.22–6.42)
Ovary (C56) – 0.15 1 6.83 (0.17–38.05) 0.15 1 6.55 (0.17–36.50)
Prostate (C61) – – 0.89 1 1.12 (0.03–6.25)
Kidney (C64) 0.51 2 3.92 (0.47–14.15) 0.34 1 2.93 (0.07–16.31) 0.33 1 3.07 (0.08–17.12)
Bladder (C67) 0.65 3 4.62 (0.95–13.51) – 0.33 1 3.07 (0.08–17.10)
Thyroid (C73) – 1.38 1 0.72 (0.02–4.02) 1.68 1 0.59 (0.02–3.31)
Hematological cancer 1.02 6 5.86 (2.15–12.75) 0.65 12 18.40 (9.51–32.15) 0.61 8 13.20 (5.70–26.01)
Hodgkin lymphoma (C81) – – 0.01 1 72.78 (1.84–405.58)
Non-Hodgkin lymphoma (C82–C85, C96) 0.57 1 1.75 (0.04–9.75) 0.37 7 19.08 (7.67–39.31) 0.34 5 14.56 (4.73–33.99)
Multiple myeloma (C90) 0.22 5 22.54 (7.32–52.59) 0.13 3 22.29 (4.60–65.15) 0.12 2 17.10 (2.07–61.78)
Leukemia (C91–C95) – 0.14 2 14.52 (1.76–52.47) –
Other (remaining cancer codes) 3.37 4 1.19 (0.32–3.03) 2.11 13 6.15 (3.27–10.51) 1.91 6 3.13 (1.15–6.82)
AAV: ANCA-associated vasculitis; ANCA: Antineutrophil cytoplasmic antibody; ICD: International classification of diseases; MPA: Microscopic polyangiitis; GPA: Granulomatosis with
polyangiitis; EGPA: Eosinophilic granulomatosis with polyangiitis.
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3.5. Risk of Cancer Based on Immunosuppressive Agent Usage
We divided our patients into ever- and never-users of cyclophosphamide, rituximab,
azathioprine/mizoribine, and methotrexate prior to the diagnosis of cancer and estimated the SIRs
for cancer development. As shown in Supplementary Table S1 and S2, the risk for overall cancer was
higher in patients treated with immunosuppressants, except in those treated with rituximab. However,
patients treated with rituximab had an increased risk of the site-specific kidney cancer (C64) (SIR 15.39,
95% CI 1.86–55.61) and non-Hodgkin lymphoma (C82–C85, C96) (SIR 14.47, 95% CI 1.75–52.26).
Patients who were treated with cyclophosphamide had significantly higher risks of lung cancer
(C33–C34) (SIR 2.32, 95% CI 1.11–4.27), kidney cancer (C64) (SIR 5.01, 95% CI 1.03–14.63), hematological
cancer (SIR 13.82, 95% CI 7.90–22.45), and the remaining cancers (SIR 3.51, 95% CI 1.87–6.00). Patients
that were administered with azathioprine/mizoribine had higher risk of kidney cancer (C64) (SIR 5.46,
95% CI 1.13–15.96), hematological cancer (SIR 5.67, 95% CI 2.08–12.35), and the remaining cancers
(SIR 3.25, 95% CI 1.62–5.81). Methotrexate users showed an increased risk of hematological cancer
(SIR 17.72, 95% CI 6.50–38.57) and remaining cancers (SIR 7.44, 95% CI 3.21–14.66).
In addition, a nested case-control analysis was performed to elucidate whether the use of
immunosuppressive agents was associated with the risk of cancers among AAV patients. In the
adjusted analysis, the use of glucocorticoid for ≥1 year (OR 4.20, 95% CI 1.47–12.01, p = 0.0075), the use
of cyclophosphamide (OR 1.75, 95% CI 1.03–2.96, p = 0.0385), and the use of methotrexate (OR 2.39,
95% CI 1.12–5.13, p = 0.0247) were found to be independently associated with the development of
cancers (Table 5).
Table 5. Factors associated with the development of cancer among patients with AAV.
Crude Odds Ratio a Adjusted Odds Ratio
Odds Ratio 95% CI p-Value Odds Ratio 95% CI p-Value
Type of insurance
National Health Insurance 1.0 (ref) 1.0 (ref)
Medical Aid 1.11 (0.38–3.28) 0.8508 1.47 (0.47–4.57) 0.5092
Glucocorticoid usage ≥ 1 year 4.36 (1.61–11.84) 0.0039 4.20 (1.47–12.01) 0.0075
Cyclophosphamide 1.78 (1.08–2.93) 0.0239 1.75 (1.03–2.96) 0.0385
Rituximab 0.78 (0.24–2.49) 0.6731 0.56 (0.17–1.92) 0.3591
Azathioprine/mizoribine 1.33 (0.77–2.30) 0.3087 0.94 (0.50–1.75) 0.8347
Methotrexate 2.27 (1.11–4.63) 0.0247 2.39 (1.12–5.13) 0.0247
a In the nested case-control analysis, the selected cases were matched for sex, age, AAV index date, duration, and
type of diagnosis. AAV: ANCA-associated vasculitis; ANCA: Antineutrophil cytoplasmic antibody.
3.6. Overall, Hematological, and Lung Cancer Risks in Patients with AAV According to Age
Finally, we evaluated whether there was a difference in the risk of cancer according to age groups.
Because the risks for overall cancer, hematological, and lung cancer were significantly increased
compared to those in the general population, the SIRs for those three groups were evaluated according
to age. Regarding the risk of overall cancer in AAV patients, the risk was higher across all age groups
except in those ≥80 years old. However, in males, the risk of cancer was higher in the age groups of
<50, 50–59, and 60–69 years old. In contrast, in females, patients <50, 70–79, and ≥80 years old were at
increased risk of overall cancers (Figure 1a).
For hematological cancers, the risk was higher in those <50, 50–59, and 70–79 years old among
AAV patients, whereas the risk was found to be elevated in those <50, 50–59, and 70–79 years old
among males and <50, 50–59, and 70–79 years old among females (Figure 1b). Regarding lung cancer,
the risk was only significantly increased in those who were 60–69 years old in AAV patients (Figure 1c).
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4. Discussion
Although it is now becoming increasingly evident that the risk of cancers is elevated in subjects
with AIDs, the temporal relationship between AAV and cancer remains unclear. In the present study,
we assessed the risk of cancer in patients with AAV by utilizing the Korea National Health Insurance
Claims Database. The observations from our study indicated that among the patients included,
a substantial proportion of AAV patients (5.4%) developed cancer during the follow-up period. Overall,
patients affected with AAV had a significantly higher risk of developing cancers (SIR 1.90) compared
to the general population, which is comparable to results previously reported in the literature [28].
Moreover, regarding site-specific cancers, the risks of lung and hematologic cancers were especially
higher compared to those in the general population. Additionally, the diagnosis of GPA and the
administration of immunosuppressive agents except rituximab were associated with an increased risk
of overall cancer. The findings from our study have important implications in the management of AAV.
In general, chronic inflammation is associated with the risk of cancers by altering the immune
response [29], and both systemic and localized inflammation in AIDs may contribute to the development
of cancer. The effect of inflammation on tumorigenesis is a complicated process mediated by the
release of cytokines, chemokines, and growth factors; the promotion of angiogenesis; and damage
to DNA [30,31]. In addition, functional defects are found in the regulatory T cell populations in
AIDs, which could lead to cancer progression by the suppression of anti-tumor surveillance [32,33].
In this study, we found that the risks of site-specific lung and hematologic cancers are significantly
elevated in patients with AAV. This could be explained by the fact that pulmonary involvement is a
common manifestation in AAV and autoimmunity is closely linked to the development of hematologic
cancers as a consequence of abnormal cellular lineage expansion and the impaired clearance of
autoreactive lymphocytes [34–36]. In addition, immunosuppressive drugs that are used to treat AAV
could either indirectly affect the immune response by hampering the clearance of cancer cells under
homeostatic conditions or directly promote carcinogenesis. These hypotheses are supported by the
results from previous studies that have demonstrated that immunocompromised individuals, such
as organ recipients and patients with human immunodeficiency virus infections, are at higher risk
of developing cancers [37,38]. In addition, compelling experimental evidence suggests that chronic
exposure to immunomodulatory drugs may accelerate or initiate the process of carcinogenesis [39,40].
To identify the incidence of de novo cancers in patients with AAV, we excluded patients with a
history of cancer before the index date of AAV. Surprisingly, we found that a considerable number of
patients (n = 328) were excluded due to their history of cancer upon patient selection. Furthermore,
the mean follow-up duration of patients with cancer was 1.5 years, which was relatively short. These
findings appear to be in accordance with the results in previous studies, which showed that the
incidence of cancer was most prominent during the period of diagnosis in patients with inflammatory
myositis [41,42]. However, we were not able to calculate the SIRs of cancers prior to the diagnosis of
AAV because the obtained data were not indicative of the exact period of the diagnosis of cancer before
the onset of AAV. In addition, because a recent study has also suggested that the risk of malignancy
prior to the diagnosis of AAV was not elevated, future studies are required to elucidate whether
preceding cancer can directly promote the development of AAV [43].
In this study, we found a significantly heightened incidence of overall cancer in AAV patients.
Meanwhile, in a subgroup analysis based on sex and the subtypes of AAV, a different pattern of
cancer incidence was found. Briefly, the risks of gallbladder, lung, and hematologic cancers were
higher in males, whereas the risks of bladder, hematologic cancer, and the remaining cancers were
higher in females. However, the higher risk of NMSC in AAV, which was found to be the most
prominent site-specific cancer in the Western world, was not observed herein. In addition, among
subgroups of AAV, the SIRs for overall cancer were the highest in subjects with GPA, which is
consistent with a previous report [18]. In particular, the higher risk of lung cancer in GPA seems to be
convincing because a common clinical feature of GPA is the involvement of the respiratory tracts [44].
Notably, patients with EGPA were also at increased risk of cancers, with a similar incidence pattern of
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site-specific cancers except lung cancer, compared to GPA. These findings imply the need for a different
approach with regard to the type of cancer depending on sex and the subtypes of AAV, as well as the
geographic location.
Previous studies have reported that the administration of immunosuppressive agents is associated
with the incidence of cancers. It has been demonstrated that methotrexate and azathioprine, which
are widely used drugs for the treatment of AIDs, confer a higher risk of cancers [45,46]. Our data
demonstrated that all treatments except rituximab were associated with an increased risk of overall
cancer. This finding is in line with that of a recent publication by van Daalen et al. [47] in which
rituximab treatment for AAV was not associated with the risk of cancer compared to the general
population. On the other hand, although it has been suggested that the use of cyclophosphamide
was associated with the risk of bladder cancer [48], the risk of bladder cancer was not elevated in
this study. This non-significant association seems to be related to the lower cumulative dose of
cyclophosphamide used, as cyclophosphamide is now usually used to induce remission in AAV.
Accordingly, the cyclophosphamide dose used for AAV may not be sufficiently high to induce
carcinogenesis in the bladder [49]. However, because patients treated with immunosuppressive agents
generally had a higher risk of cancers and a distinct pattern of site-specific cancer incidence, it is essential
to find measures to optimize the control of the disease while minimizing the use of immunosuppressants.
This is further emphasized by the fact that the administration of cyclophosphamide and methotrexate
and longer usage of glucocorticoids were independent factors associated with the development of
cancer in a nested case-control study among patients with AAV.
Age is an important factor related to the development of cancer in the general population [50].
Notably, in the present study, an increased risk of cancer was found in AAV patients across all age
groups with the only exception in those ≥ 80 years old. In addition, a similar trend was found in
males, with a tendency towards increased SIRs with decreasing age. Interestingly, AAV patients
who were <50 years and 50–59 years old had significantly higher SIRs for overall and hematological
cancers compared to the other age groups. Given that younger subjects are less likely to be affected
by cancer, these results suggest that special attention and active measures to detect the occurrence of
cancers (e.g., routine health screening programs) should be provided even in younger AAV subjects,
particularly in those <60 years old.
In this study, the proportion of patients with EGPA was 27.7%, which was higher compared to
the proportion of patients with EGPA among AAV in the reports from Japan [51,52]. Even though the
exact cause of this finding is unclear, difference in the methods applied (ICD-10 codes were used to
extract patient data in our study and 2007 European Medicines Agency criteria were applied to those
with the diagnosis of AAV in the study from Japan) and the inclusion of renal-limited and unclassified
vasculitis could have resulted in the discrepant results. However, recent publication from our group
using a tertiary hospital data revealed that the proportion of patients with EGPA was similar to the
present study [53], also suggesting that a regional difference could be present.
The main strength of this study is that this is the first study to assess the risk of cancer in patients
with AAV in Asia by using a database that encompasses the information for all healthcare beneficiaries
in a single country. In addition, the number of patients included is the largest thus far in studies
assessing the risk of cancer in patients with AAV. However, there are several limitations in our study.
First, the exact number of patients with AAV may have been underestimated. Because we have defined
our patients as having AAV based on ICD-10 codes and the use of glucocorticoids, patients who
were not treated for AAV and those who received medical treatment without glucocorticoids may
have been excluded from the study. Moreover, patients with renal-limited vasculitis and unclassified
vasculitis could not be searched because the ICD-10 codes are not available for these diseases, which
could have also influenced the result of our study. Second, conventional risk factors for cancer in
the general population, such as alcohol consumption, smoking (especially for lung cancer), dietary
habits, complications, and genetic factors could not be investigated, and direct interpretation of the
results of this study should be made with caution [54]. Third, more detailed AAV-specific variables,
J. Clin. Med. 2019, 8, 1871 12 of 15
including ANCA serotypes, disease activity, and the associations between organ-specific involvement
and cancers, were not obtainable. Fourth, the cumulative dose of immunosuppressive agents related
to cancer incidence was not calculable. Finally, the use of calcineurin inhibitors (tacrolimus and
cyclosporine) and intravenous immunoglobulin therapy could not be investigated because the use of
either agent is not currently covered by the NHI and is not recorded in the HIRA database.
5. Conclusions
In summary, we have demonstrated that compared to the general population, AAV patients have
an increased overall risk of cancer and increased risks of site-specific lung and hematological cancers.
In addition, different patterns of cancer incidence were found according to age, sex, AAV subtypes, and
the usage of immunosuppressive agents. The findings from our study imply that regular monitoring
of cancers and efforts to minimize the administration of immunosuppressive agents in the treatment of
AAV are necessary.
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